Scale -


  • PBT is 180 Rs Cr; Annual Growth is 31 %; Continuous Growth over 3 years
  • PAT is 647 Rs Cr; Annual Growth is 73 %; 5 Year CAGR is 12 %
  • Revenue is 3129 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 23 %
  • Ebitda is 1128 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 22 %

Profitability -


  • PAT Margin is 20.68 %; Annual Growth is 60 %; in Top Quartile; 5 Year CAGR is -9 %
  • PBDIT Margin is 36.04 %; Continuous Growth over 3 years; in Top Quartile
  • Quarterly Ebitda Margin is 34 %; in Top Quartile

Return -


  • ROCE is 16.04 %; Annual Growth is 26 %; Continuous Growth over 3 years
  • ROA is 8.41 %; Annual Growth is 68 %; 5 Year CAGR is -17 %
  • ROE is 15.87 %; Annual Growth is 29 %
  • Asset Turnover is 43 %; Continuous Growth over 3 years; in Bottom Quartile

Efficiency -


  • Inventory Turnover Ratio is 8.11; in Top Quartile; 5 Year CAGR is 58 %
  • Operating cash flow is 538 Rs Cr; Annual Decline is -49 %
  • Current Ratio is 0.74; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -30 %
  • Quick Ratio is 0.53; Continuous Decline over 3 years; in Bottom Quartile; 5 Year CAGR is -32 %

Solvancy -


  • Debt/Equity is 0.59; Annual Decline is -31 %; Continuous Decline over 3 years; in Top Quartile; 5 Year CAGR is 133 %
  • Long term Debt is 956 Rs Cr; Annual Decline is -45 %; in Top Quartile; 5 Year CAGR is 115 %
  • Total Debt is 2310 Rs Cr; Continuous Decline over 3 years; 5 Year CAGR is 168 %
  • Contingent Liabilities is 243 Rs Cr; Annual Growth is 257 %; 5 Year CAGR is 73 %

Quality -


  • Other Expenses/Total Expenses is 26 %; Continuous Decline over 3 years
  • Operating cashflow/ebitda is 48 %; Annual Decline is -54 %; in Bottom Quartile
  • Operating cashflow/PAT is 83 %; Annual Decline is -71 %
  • Change in Inventories/Total Expenses is -1 %; Annual Growth is 41 %

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Eris Lifesciences to host investor meet in Mumbai on November 19
Buy Eris Lifesciences; target of Rs 1500: Prabhudas Lilladher
Dalmia Bharat, APL Apollo Among 12 Stocks Reviewed By HDFC Securities After Q2 Results; Check New Target Prices
Eris Life revenue rises 12.6% to ?892 crore in Q2 FY27
Eris Lifesciences (NSEI:ERIS) Stock Price
Eris Lifesciences expects 150-200 bps margin improvement in H2 as biologics scale up
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026
Eris Lifesciences Q2 Profit Jumps 39% to Rs 187 Cr
Earnings call transcript: Eris Lifesciences posts stronger profit growth in Q2 2026 By Investing.com
Eris Lifesciences (NSE:ERIS) Q2 FY27 Update on Plants, Pipeline and Merger
Eris Lifesciences Board Meets To Approve Q2 Financial Results
Eris Lifesciences Limited Reports Unaudited Standalone and Consolidated Financial Results for Q2 and H1 FY 2026-27
Eris Lifesciences profit rises 39% to ?187 crore in Q2
Eris Lifesciences Q2 Results: ????????? ?????? ???? ???! ??? **??? ???????**
Eris Lifesciences Taps Chirag Mehta as Executive Director for Finance, Global Business
Eris Life names Chirag Mehta as Executive Director
Eris Lifesciences accepts COO Krishnakumar Vaidyanathan's resignation